{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 60,
  "pageCount": 239,
  "prevPage": 59,
  "nextPage": 61,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses direct quotes to undermine the credibility of the company's primary clinical evidence.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/60",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-60",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "There was a lot of bias in the Nevro pivotal trial. We had to talk people into the study, and then they'd go home and pray they got the new stimulator and then they'd get the old one and be grumpy. It wasn't a pristine way to set up a study.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b33b-4827df0135b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.88,
        "x": 0.06,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "We conducted a detailed interview with a key, influential player in the SENZA-RCT trial, a prominent physician in the pain space. His proximity to the trial cannot be overstated, making him intimately knowledgeable about what actually occurred. Shockingly, he conveyed personal discomfort with the conduct of the study, that he didn’t believe the results, that he hadn’t moved his patients to Nevro’s device, and that the entire high frequency premise was false. We have never seen a trial investigator – a recipient of money from Nevro and someone friendly with and sympathetic to Nevro’s management – so readily contradict the party line. His comments were so blunt that we simply asked “Do you think the Nevro pivotal study you conducted was bs?” to which he replied:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ce670f3-760c-4d26-af9e-38586a847657",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.88,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "quote",
      "text": "“I’m different than most guys Nevro markets to. I need higher evidence. I haven’t switched my patients over to Nevro.” – KOL and key player in the SENZA-RCT pivotal trial",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6001a29f-489e-4d18-8f98-12ada0ceb533",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.88,
        "x": 0.06,
        "y": 0.56
      },
      "kind": "quote",
      "text": "“I hope the study wasn’t bs. It does bother me. I’m going to say it was done honestly. It’s just that as the study unfolded, I could see the bias.”",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93f8e78f-518e-4416-a765-690137f8afe1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.88,
        "x": 0.06,
        "y": 0.44
      },
      "kind": "quote",
      "text": "“There was a lot of bias in the Nevro pivotal trial. We had to talk people into the study, and then they’d go home and pray they got the new stimulator and then they’d get the old one and be grumpy. It wasn’t a pristine way to set up a study.”",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a430a8b-8c36-4ac5-b86c-4ffec73ae1c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "There was a lot of bias in the Nevro pivotal trial. We had to talk people into the study, and then they'd go home and pray they got the new stimulator and then they'd get the old one and be grumpy. It wasn't a pristine way to set up a study. I hope the study wasn't bs. It does bother me. I'm going to say it was done honestly. It's just that as the study unfolded, I could see the bias. I'm different than most guys Nevro markets to. I need higher evidence. I haven't switched my patients over to Nevro. — KOL and key player in the SENZA-RCT pivotal trial",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b33b-4c148f803018",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Consultation call with expert",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8639ab1b-abb8-456b-9360-579b1db77c43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.88,
        "x": 0.06,
        "y": 0.1
      },
      "kind": "title",
      "text": "3. Trial investigators, KOL’s, and ex-employees painted the SENZA pivotal study as a fraud",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "092f7788-417f-43c9-9702-291846ca9468",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fb5384e-9cd5-4a2c-82b5-93a1a8da1c45",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "de06857c-bf98-4f93-aa20-6c65fda8d95c",
      "evidence": "The slide explicitly frames the clinical trial as a fraud based on expert testimony.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 60,
      "from": 50,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d046baf7-54ed-409a-b6fc-7a2d900bc1ce",
      "evidence": "The deck emphasizes the risks of not addressing Nevro's problems",
      "position": 1,
      "objective": "Highlight the cost of inaction",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}